Tandem Diabetes Care Stock News

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2023 results aft

Investors remain optimistic about Tandem Diabetes (TNDM), backed by strategic developments and innovative new launches.

This segment originally aired on October 5, 2023 Weight loss drugs, like Novo Nordisk's (NVO) Ozempic, have become popular across healthcare providers in regard to diabetes treatment. Although use is

In recent months, diabetes stocks have retreated sharply, partly due to the increased popularity of the weight-loss drug Semaglutide. Some have contended that Semaglutide will greatly reduce the numbe

Wall Street says insulin pump maker Insulet and Tandem Diabetes, as well as glucose-monitor maker DexCom, look ready to rise after pressure from Novo Nordisk's Wegovy and Eli Lilly.

Shares of Tandem Diabetes Care and Teladoc Health haven't performed well recently. Tandem still has a long way to go in the insulin-pump space and demand should grow.

Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.

Teladoc's solid position in telemedicine, improving bottom line, and strong margins make a solid case for the stock. Tandem Diabetes Care develops cutting-edge insulin pumps for diabetes patients, an

Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business.

Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.24 per share a year ago.

CVS Health's broad array of healthcare services makes it an excellent long-term pick. Tandem Diabetes Care can still benefit from the vast untapped market within its niche.

Tandem Diabetes Care's stock is down 33% so far this year. The company got off to a sluggish first quarter.

Tandem Diabetes (TNDM) receives FDA clearance for the world's smallest AID system, Tandem Mobi.

Tandem Diabetes Care, Inc. (TNDM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further p